Jeil Pharmaceutical (CEO Seong Seok-je) and Amgen Korea (CEO Noh Sang-kyung) announced on the 7th that they signed a joint sales contract for Repatha for patients with atherosclerosis cardiovascular disease and hypercholesterolemia as of the 1st of this month.

With this joint sales contract, Jeil Pharmaceutical and Amgen Korea will conduct Repatha's sales and marketing activities at hospitals, and Jeil Pharmaceutical will be in charge of sales and marketing activities for clinics. Through Repatha's joint sales cooperation, the two companies expected synergy to provide improved treatment benefits for patients with ultra-high-risk cardiovascular systems in Korea and strengthen market competitiveness.